In young patients with essential thrombocythemia and early significant atherosclerotic disease but no thrombotic history, would you consider the addition of cytoreductive therapy?

This is a good question without an evidence-based answer. It's important to understand why this person has early atherosclerotic disease, have other modifiable risk factors been identified and addressed? For example, familial conditions that lead to hyperlipidemia, or smoking, obesity, etc. If the p...